Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Hussaini I
orally active and selective CCR5 entry inhibitor of HIV-1 (IC50 = 0
ethyl ester
quickly equilibrating with the central nervous system
Administration of Cariprazine (30 µg/kg) reduces the striatal uptake of both radioligands to the level of nonspecific binding compared with baseline PET measurements
Ruxolitinib sulfate - CAS# 1092939-16-6 alog 2 Hussaini IRuxolitinib sulfate is the first potent, selective JAK1 2 inhibitor to enter the clinic with IC50s of 3. 3 nM 2. 8 nM, and has > 130 fold selectivity for JAK1 2 versus JAK3. Ruxolitinib potently and selectively inhibits JAK2V617F mediated signaling and proliferation, markedly increases apoptosis in a dose dependent manner, and at 64 nM results in a doubling of cells with depolarized mitochondria in Ba F3 cells. Ruxolitinib demonstrates remarkable
US$ 38.00
US$ 68.00
US$ 68.00
US$ 38.00
US$ 50.00
US$ 68.00
US$ 75.00
US$ 38.00